Limited Processing of Pro-Matrix Metalloprotease-2 (Gelatinase A) Overexpressed by Transfection in PC-3 Human Prostate Tumor Cells: Association with Restricted Cell Surface Localization of Membrane-Type Matrix Metalloproteinase-1

Journal of Andrology

Volumn 25, Issue 2, 2004, Pages 274-285

  Wilson, Michael J ^a,b,c   Jiang, Aixiang ^c   Wiehr, Carol ^a   Wang, Xing ^c   Sinha, Akhouri A ^a,c   Pei, Duanqing ^c  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Concanavalin A; Prostate cancer; Reverse transcriptase polymerase chain reaction; Tissue inhibitor of metalloproteinase 2

Indexed keywords

ANTIBIOTIC G 418; CONCANAVALIN A; CYCLIC AMP; ENZYME PRECURSOR; GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; PLASMID VECTOR; SERINE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL MEMBRANE; CELL STRAIN; CELL STRAIN HT 1080; CELL STRAIN PC 3; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VECTOR CONTROL; ZYMOGRAPHY;

EID: 1242297705     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1939-4640.2004.tb02788.x     Document Type: Article

References (73)

1. Aillenberg M, Silverman M. Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activalor (MT-MMP). Biochem J. 1996;313:879-884.
2. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM. Involvement of PA/plasmin system in the processing of pro-MMP9 and in the second step of pro-MMP-2 activation. FEBS Lett. 1997;405:157-162.
3. Basbaum CB, Werb Z. Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol. 1996;8:731-738.
4. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproleinases: it review. Crit Rev Oral Biol Med. 1993;4:197-250.
5. Boag AH, Young ID. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma: demonstration by immunohistochemistry and in situ hybridization. Am J Pathol. 1994;144:585-591.
6. Brassart B, Randoux A, Hornebeck W, Emonard H. Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosarcoma cell line. Clin Exp Metastasis. 1998;16:489-500.
7. Brooks PC, Stromblad S, Sander LC, Von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996;85:683-693.
8. Brown PD, Levy AT, Marguilies IMK, Liotta LA, Stetler-Stevenson WG. Independent expression and cellular processing of Mr 72.000 type VI collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 1990;50:6184-6191.
9. Butler GS, Buler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. J Biol Chem. 1998;273:871-880.
10. Cao J, Rehemtulla A, Bahou W, Zucker S. Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem. 1996;271:30174-30180.
11. Cockett MI, Murphy G, Birch ML, O'Connell JP, Crabbe T, Millican AT, Hart IR, Docherty AJP. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp. 1998;63:295-313.
12. Coleman P, Patel PD, Cwikel BJ, Rafferty UM, Sznycer-Luszuk R, Gelehter TD. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986;261:4352-4357.
13. Cowell S, Knauper V, Stewart MIL, et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A. gelatinase B, and collagenase 3. Biochem J. 1998;331:453-458.
14. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer. 2001;93:507-515.
15. Emmert-Buck MR, Emonard HP, Corcoran ML, Krutzsch HC, Foidart JM, Stetler-Stevenson WG. Cell surface binding of TIMP-2 and proMMP-2/TIMP-2 complex. FEBS Lett. 1995;364:28-32.
16. Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Abini A, Bologna M. Osteoblast-drived TGF-β1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer. 2000;85:407-415.
17. Greene FG, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD, Fidler IJ. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol, 1997;150:1571-1582.
18. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem. 1980;102:186-202.
19. Hoffman UB, Westphal JR, Van Kraats AA, Rutter DJ, Van Muijen GNP. Expression of integrin avβ3 correlates with a activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer, 2000;87:12-19.
20. Ito A, Yamada M, Sato T, Sanekata K, Sato H, Seiki M, Nagase H, Mori Y. Calmodulin antagonists increase the expression of membrane-type-1 matrix metalloproteinase in human uterine fibroblasts. Eur J Biochem. 1998;251:353-358.
21. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Sueaga N, Aoki T, Seiki M. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 2001;20:4782-4793.
22. Jung K, Lein M, Ulbrich N, Rudolph B, Henke W, Schnorr D, Loening SA. Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostatic tissue: analytical aspects. Prostate. 1998;34:130-136.
23. Jung M, Romer A, Keyszer G, Lein M, Kristiansen G, Schnorr D, Loening SA, Jung K. mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue. Prostate. 2003;55:89-98.
24. Kawamata H, Kameyama S, Kawai K, Tanaka Y, Nan L, Barch DH, Stetler-Stevenson WG, Oyasu R. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer. 1995;63:568-575.
25. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res. 2000;6:2295-2308.
26. Lafleur MA, Hollenberg MD, Atkinson SJ, Knauper V, Murphy G, Edwards DR. Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J. 2001;357:107-115.
27. Lee AY, Akers KT, Collier M, Li L, Eizen AZ, Seltzer JL. Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts. Proc Natl Acad Sci U S A. 1997;94:4424-4429.
28. Lehti K, Valtanen H, Wickstrom S, Lohi J, Keski-Oja J. Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain. J Biol Chem. 2000;275:15006-15013.
29. Li L, Akers K, Eisen AZ, Seltzer JL. Activation of gelatinase A (72-kDa type IV collagenase) induced by monensin in normal human fibroblasts. Exp Cell Res. 1997;232:322-330.
30. Li L, Eisen AZ, Sturman E, Seltzer JL. Protein tyrosine phosphorylation in signaling pathways leading to the activation of gelatinase A: activation of gelatinase A by treatment with the protein tyrosine phosphatase inhibitor sodium orthovanadate. Biochim Biophys Acta. 1998;1405:110-120.
31. Lohi J, Keski-Oja K. Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. J Biol Chem. 1995;270:17602-17609.
32. Lohi J, Lehti K, Westermarck J, Kahari V-M, Keski-Oja J. Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem. 1996;239:239-247.
33. Lohi JL, Wilson CL, Roby JD, Parks WC. Epilysin: a novel human matrix metalloproteinase (MMP-27) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 2001;276:10134-10144.
34. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. Secretion of matrix-metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res. 1993;53:4493-4498.
35. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998;12:1075-1095.
36. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol. 2001;13:534-540.
37. Montironi R, Fabris G, Lucarini G, Biagini G. Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. Pathol Res Pract. 1995;191:1140-1146.
38. Montironi R, Lucarini G, Castaldini C, Galluzzi CM, Biagini G, Fabris G. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res. 1996;16:2057-2062.
39. Murphy G, Reynolds JJ, Hembry RM. Metalloproteinase and cancer invasion and metastasis. Int J Cancer. 1989;44:757-760.
40. Nagakawa O, Murakami K, Yamamura T, Fujiuchi Y, Murata J, Fuse H, Saiki I. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett. 2000;155:173-179.
41. Nagase H, Suzuki K, Itoh Y, Kan CC, Gehring MR, Huang W, Brew K. Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Adv Exp Med Biol. 1996;389:23-31.
42. Nguyen M, Arkell J, Jackson CJ. Thrombin rapidly and efficiently activates gelatinase A in human microvascular endothelial cells via a mechanism independent of active MT1 matrix metalloproteinase. Lab Invest. 1999;79:467-475.
43. Overall CM, Sodek J. Concanavalin A produces a matrix-degradative phenotype in human fibroblasts: induction and endogenous activation of collagenase, 72-kDa gelatinase, and pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. J Biol Chem. 1990;265:21141-21151.
44. Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX. Protein, nucleotide identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem. 2000;275:20540-20544.
45. Pei D. Identification and characterization of the fifth member of the membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem. 1999a;274:8925-8932.
46. Pei D. CA-MMP: a matrix metalloproteinase with a novel cysteine-array, but without the classic cysteine switch. FEBS Lett. 1999b;457:262-270.
47. Pei D. MMP25/MT6-MMP/Leukolysin: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res. 1999c;9:291-303.
48. Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem. 1996;271:9135-9140.
49. Reeke GN Jr, Becker JW, Cuningham BA, Gunther GR, Wang JL, Edelman GM. Relationships between the structure and activities of Concanavalin A. Ann N Y Acad Sci. 1974;234:369-382.
50. Romijin JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate. 1988;12:99-110.
51. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J Cell Biol. 1989;109:309-315.
52. Seltzer JL, Lee A-Y, Akers KT, Sudbeck B, Southon EA, Wayner EA, Eisen AZ. Activation of 72-kDa type IV collagenase/gelatinase by normal fibroblasts in collagen lattices is mediated by integrin receptors but is not related to lattice contraction. Exp Cell Res. 1994;213:365-374.
53. Shofuda K-I, Moriyama K, Nishihashi A, et al. Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. J Biochem. 1998;124:462-470.
54. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2) expression associated with human prostate cancer progression. Oncol Res. 1996;8:69-75.
55. Stearns ME, Wang M. Regulation of kinensin expression and type IV collagenase secretion in invasive human prostate PC-3 tumor sublines. Cancer Res. 1991;51:5866-5875.
56. Stearns ME, Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 1993;53:878-883.
57. Steffensen B, Bigg HF, Overall CM. The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation. J Biol Chem. 1998;273:20622-20628.
58. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999;103:1237-1241.
59. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate. 2000;42:18-25.
60. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase: isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331-5338.
61. Upadhyay J, Shekarriz B, Nemeth JA, et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate cancer: change in cellular localization associated with high-grad prostatic intraepithelial neoplasia. Clin Cancer Res. 1999;5:4105-4110.
62. Vassali JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 1987;214:187-191.
63. Ward RV, Atkinson SJ, Slocombe PM, Docherty AJP, Reynolds JJ, Murphy G. Tissue inhibitor of metalloprotienases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta. 1991;1079:242-246.
64. Wick M, Burger C, Brusselbach S, Lucibello FC, Muller R. A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during G1 progression, mitogenic stimulation, differentiation, and senescence. J Biol Chem. 1994;269:18953-18960.
65. Wilson MJ. Proteases in prostate development, function, and pathology. Microsc Res Tech. 1995;30:305-318.
66. Wilson MJ, Norris H, Kapoor D, Woodson M, Limas C, Sinha AA. Gelatinolytic and caseinolytic proteinase activities in human prostatic secretions. J Urol. 1993;149:653-658.
67. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol. 2002;191:208-216.
68. Wilson MJ, Sinha AA. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice. Cell Mol Biol Res. 1993;39:751-760.
69. Yu M, Bowden ET, Sitlani J, Sato H, Seiki M, Mueller SC, Tompson EW. Tyrosine phosphorylation mediates ConA-induced membrane type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in MDA-MB-231 human breast carcinoma cells. Cancer Res. 1997;57:5028-5032.
70. Yu M, Sato H, Sieki M, Spiegel S, Tompson EW. Elevated cyclic MP suppresses ConA-induced MT1-MMP expression in MDA-MB-231 human breast cancer cells. Clin Exp Metastasis. 1998;16:185-191.
71. Zheng D-Q, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via αvβ3 integrins modulated by a focal adhesion kinase pathway. Cancer Res. 1999;59:1655-1664.
72. Zucker S, Conner C, DiMassmo BI, Ende H, Drews M, Seiki M, Bahou WE Thrombin induces the activation of progelatinase A in vascular endothelial cells. J Biol Chem. 1995;270:23730-23738.
73. Zucker S, Drews M, Conner C, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1(MT1-MMP). J Biol Chem. 1998;273:1216-1222.